WO2007075650A3 - Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders - Google Patents

Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders Download PDF

Info

Publication number
WO2007075650A3
WO2007075650A3 PCT/US2006/048382 US2006048382W WO2007075650A3 WO 2007075650 A3 WO2007075650 A3 WO 2007075650A3 US 2006048382 W US2006048382 W US 2006048382W WO 2007075650 A3 WO2007075650 A3 WO 2007075650A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pyrimidine derivatives
cancer
treatment
substituted pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048382
Other languages
French (fr)
Other versions
WO2007075650A2 (en
Inventor
Roger Smith
Jacques Dumas
Gan Wang
Wendy Lee
Karl Miranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to ES06845790.2T priority Critical patent/ES2480440T3/en
Priority to US12/158,524 priority patent/US8580798B2/en
Priority to CA2634084A priority patent/CA2634084C/en
Priority to JP2008547428A priority patent/JP5331485B2/en
Priority to EP06845790.2A priority patent/EP1973897B1/en
Publication of WO2007075650A2 publication Critical patent/WO2007075650A2/en
Publication of WO2007075650A3 publication Critical patent/WO2007075650A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A= pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies.
PCT/US2006/048382 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders Ceased WO2007075650A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES06845790.2T ES2480440T3 (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
US12/158,524 US8580798B2 (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CA2634084A CA2634084C (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
JP2008547428A JP5331485B2 (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful for the treatment of cancer and other disorders
EP06845790.2A EP1973897B1 (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75220005P 2005-12-21 2005-12-21
US60/752,200 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007075650A2 WO2007075650A2 (en) 2007-07-05
WO2007075650A3 true WO2007075650A3 (en) 2007-11-15

Family

ID=38091685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048382 Ceased WO2007075650A2 (en) 2005-12-21 2006-12-20 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

Country Status (7)

Country Link
US (1) US8580798B2 (en)
EP (1) EP1973897B1 (en)
JP (1) JP5331485B2 (en)
KR (1) KR20080089410A (en)
CA (1) CA2634084C (en)
ES (1) ES2480440T3 (en)
WO (1) WO2007075650A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (en) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн N,n-diphenyl urea derivative, pharmaceutical composition (embodiments) thereof, and method for the treatment and prevention of diseases and conditions using it (embodiments)
AR062927A1 (en) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE
UA121319C2 (en) * 2014-11-07 2020-05-12 Сінгента Партісіпейшнс Аг PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR-CONTAINING SUBSTANCES
EP3500257B1 (en) * 2016-08-17 2025-07-02 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
WO1999032111A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
WO1999032106A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032110A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2002062763A2 (en) * 2001-02-07 2002-08-15 Bayer Corporation Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2002085857A2 (en) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2004078747A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100522934C (en) 1999-01-13 2009-08-05 拜尔有限公司 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE60137273D1 (en) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Process for the preparation of 4-phenoxyquinoline derivatives
DE602004030222D1 (en) 2003-02-28 2011-01-05 Bayer Healthcare Llc 2-OXO-1,3,5-PERHYDROTRIAZAPIN DERIVATIVES SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVES, ANGIOGENS AND INFLAMMATORY DISEASES
EP1603879A2 (en) * 2003-02-28 2005-12-14 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US20070161677A1 (en) 2004-01-30 2007-07-12 Merck Patent Gmbh Bisarylurea derivatives
WO2006071940A2 (en) * 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032455A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
WO1999032111A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
WO1999032106A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032110A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US20020165394A1 (en) * 1999-01-13 2002-11-07 Bayer Corporation Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002062763A2 (en) * 2001-02-07 2002-08-15 Bayer Corporation Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2002085857A2 (en) * 2001-04-20 2002-10-31 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20030207914A1 (en) * 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2004078747A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders

Also Published As

Publication number Publication date
ES2480440T3 (en) 2014-07-28
EP1973897A2 (en) 2008-10-01
CA2634084C (en) 2015-04-07
US8580798B2 (en) 2013-11-12
CA2634084A1 (en) 2007-07-05
WO2007075650A2 (en) 2007-07-05
US20100081812A1 (en) 2010-04-01
JP2009521449A (en) 2009-06-04
JP5331485B2 (en) 2013-10-30
KR20080089410A (en) 2008-10-06
EP1973897B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004078747A8 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078746A3 (en) 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE456565T1 (en) PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009012000A (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis.
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2009091550A3 (en) Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
WO2004078748A3 (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
WO2007052123A3 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
WO2006116733A3 (en) Protein kinase inhibitors
TW200639156A (en) New compounds
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
IL206397A (en) Compounds exhibiting cytotoxic activity, pharmaceutical compositions containing same and uses thereof in the manufacture of medicaments for treating tumors
WO2007075650A3 (en) Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
MX2008011769A (en) Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents.
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
WO2008098077A3 (en) Substituted alkine derivatives as anti-cancer agents
WO2008107398A3 (en) Pyrazine compounds
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006845790

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5248/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2634084

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547428

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087017537

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12158524

Country of ref document: US